TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, is available to customers at ...

Overall survival was analyzed in real-world patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.

In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology ...

The total cost of funding the state's department that administers Medicaid topped $55 billion last year including federal ...

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.

Defect-free quadruple medication therapy significantly improved at discharge, 30 days in patients with heart failure with reduced ejection fraction.

Cytokinetics Incorporated (NASDAQ:CYTK) is one of the most active stocks to buy according to analysts. Earlier in May, ...

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ...

Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the ...

Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this double-blind, ...